مينو
Get an overview of our progressive portfolio companies that will shape and change our tomorrow. SGIP offers you an exclusive opportunity to participate in these innovative companies today. Together we will impact the future!
Vinivia:
Vinivia AG is a Swiss live streaming company and the marketleader in live streaming technologies. They are leveling up the livestreaming industry with their own social app by eliminating existing pain points of brands and creators such as content property rights and transparent monetization options. With an experienced management team and founders who have exited their previous company to Facebook, Vinivia aims to be the next Swiss unicorn.
Stage: Open for investment – raising Pre C round (CHF 20Mio)
Xlife:
Xlife Sciences AG is a Swiss company focusing on the value development and commercialization of promising early-stage research projects from universities and other research institutions in the life sciences industry with the goal to offer solutions for high unmet medical need and better life quality. Their goal is to build a bridge from research and development to the healthcare markets.
Xlife brings selected projects in the four areas of technology platforms, biotechnologies/therapies, medical technology (health technology), and artificial intelligence in the life science sector and digital health to the next stage of development.
Stage: Publicly listed
Veraxa:
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation. Through biochemical and technological innovation, we strive to transform the way antibodies and antibody-drug conjugates (ADCs) are created to develop more effective and safe therapies for patients.
With their transformative technologies, VERAXA can streamline and derisk early bioconjugate development. They have established a rich pipeline of proprietary ADCs and are collaborating with a number of partners to provide access to our unique research & development capabilities going from target to antibody to ADC.
Stage: Rounds closed, in discussions for potential IPO or Acquisition
